Gene · 970
NIH grants2,135
NIH grants whose papers are about the gene, through NIH's grant-paper links.
821 to 840 of 2,135
Download this page as JSON| Grant | Title | CD70 papers | Newest fiscal year |
|---|---|---|---|
| U01AI131339 | Development and significance of the plasma cell niche in the human infant thymus | 1 | 2021 |
| U01CA214201 | Novel approaches to study immune responses to post translational modifications for cancer detection | 1 | 2021 |
| U01CA217842 | Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer | 1 | 2021 |
| U01CA217858 | Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine | 1 | 2021 |
| U01CA224193 | Disrupting the immune and drug-privileged microenvironment in pancreas cancer | 1 | 2021 |
| U01CA242871 | The Federated Tumor Segmentation (FeTS) platform: An intuitive tool facilitating secure multi-institutional collaboration | 1 | 2021 |
| U01DP006489 | Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort & Biobank | 1 | 2021 |
| U19AI128913 | Mapping Immune Responses to CMV in Renal Transplant Recipients | 1 | 2021 |
| U54CA224068 | An integrated translational approach to overcome drug resistance | 1 | 2021 |
| U54CA224079 | The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center | 1 | 2021 |
| U54HL119145 | Boston Biomedical Innovation Center | 1 | 2021 |
| UG3TR002851 | Endothelial-targeted adenovirus for organ-selective gene editing in vivo | 1 | 2021 |
| UM1AI126620 | First-in-human study of two anti-SARS CoV-2 antibodies in health volunteers | 1 | 2021 |
| ZIAAI005027 | Cellular Immune Responses to RSV infection in Mice | 1 | 2021 |
| ZIABC010717 | Phase I study of bortezomib and DA-EPOCH-R with microarray in DLBCL | 1 | 2021 |
| ZIANR000015 | Genomic Analyses for Elucidating Novel Targets for Symptoms Management | 1 | 2021 |
| ZIABC010763 | Building on the success of the adoptive immunotherapy of cancer | 4 | 2020 |
| K08NS092895 | Plasmacytoid Dendritic Cells in Malignant Glioma | 3 | 2020 |
| R00CA212302 | Resistance To Targeted Immunotherapies:CART19 as a Paradigm | 3 | 2020 |
| R01HL132399 | IL-35 suppression of endothelial cell activation and atherosclerosis | 3 | 2020 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/grants?page=42